Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator-Reference-Cited by-同舟云学术

Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator

Published:2019-01 Issue:1 Volume:5 Page:54-61
ISSN:2405-4569
Container-title:European Urology Focus
language:en
Short-container-title:European Urology Focus

Author:

Ankerst Donna P.,Goros Martin,Tomlins Scott A.,Patil Dattatraya,Feng Ziding,Wei John T.,Sanda Martin G.,Gelfond Jonathan,Thompson Ian M.,Leach Robin J.,Liss Michael A.

Publisher

Elsevier BV

Subject

Urology

Reference17 articles.

1. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial;Thompson;J Natl Cancer Inst,2006

2. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group;Ankerst;World J Urol,2012

3. Evaluation of prostate cancer risk calculators for shared decision making across diverse urology practices in Michigan;Auffenberg;Urology,2017

4. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary Europe

5. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer;Ankerst;Urology,2014

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk calculators for the detection of prostate cancer: a systematic review;Prostate Cancer and Prostatic Diseases;2024-06-03

2. How to Integrate Prostate Cancer Biomarkers in Urology Clinical Practice: An Update;Cancers;2024-01-11

3. Liquid Biomarkers in Prostate Cancer Diagnosis: Current Status and Emerging Prospects;The World Journal of Men's Health;2024

4. Unravelling the Role of P300 and TMPRSS2 in Prostate Cancer: A Literature Review;International Journal of Molecular Sciences;2023-07-11

5. The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics;Clinical Biochemistry;2023-06